MUC5AC and asthma: successfully prepared cyclopeptide-modified lipid nanoparticles (Pep-LNPs) that can precisely deliver siRNA to human and mouse epithelial cells, significantly reducing the expression of pro-inflammatory cytokines (TSLP), modulating asthma-related signaling pathways, decreasing MUC5AC mucin secretion, alleviating airway inflammation, lowering airway hyperreactivity, and improving asthma symptoms (166).